Home
Scholarly Works
296 Dose ranging study of monalizumab (IPH2201) in...
Conference

296 Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221

Authors

Tinker A; Hirte H; Provencher D; Butler M; Ritter H; Tu D; Paralejas P; Grenier N; Hahn S; Ramsahai J

Volume

69

Pagination

pp. s97-s98

Publisher

Elsevier

Publication Date

December 1, 2016

DOI

10.1016/s0959-8049(16)32889-1

Conference proceedings

European Journal of Cancer

ISSN

0959-8049

Contact the Experts team